An N-terminal fragment of PTH
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Parathyroid Hormone (1-34) (human) (trifluoroacetate salt)

Item No. 24985

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-methionyl-L-histidyl-L-asparaginyl-L-leucylglycyl-L-lysyl-L-histidyl-L-leucyl-L-asparaginyl-L-seryl-L-methionyl-L-α-glutamyl-L-arginyl-L-valyl-L-α-glutamyl-L-tryptophyl-L-leucyl-L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-valyl-L-histidyl-L-asparaginyl-L-phenylalanine, trifluoroacetate salt
Synonyms
  • LY333334
  • PTH (1-34)
Molecular Formula
C181H291N55O51S2 • XCF3COOH
Formula Weight
4117.7
Purity
≥95%
Formulation (Request formulation change)
A lyophilized powder
Solubility(Learn about Variance in Solubility)
Water: 1 mg/ml
SMILES
[H]N[C@@H](CO)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)CC1=CC=CC=C1)=O)=O)CC2=CN=CN2)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)CC3=CNC4=C3C=CC=C4)=O)=O)=O)=O)=O)CCSC)=O)=O)=O)=O)CC5=CN=CN5)=O)=O)=O)=O)=O)CC6=CN=CN6)=O)CCSC)=O)=O)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C181H291N55O51S2.C2HF3O2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97;3-2(4,5)1(6)7/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199);(H,6,7)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-;/m0./s1
InChi Key
IAEDCJSUAROAKQ-LKMAISLMSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $250

    Add
    Product Description

    Parathyroid hormone (PTH) (1-34) is an N-terminal fragment of PTH that regulates bone remodeling.1 It is a PTH receptor agonist that binds to the PTH1 receptor (IC50 = 2 nM) and increases cAMP accumulation (IC50 = 0.22 pM) in HEK293 cells expressing human PTH1.2 PTH (1-34) also stimulates cAMP accumulation in Saos-2 human osteoblast-like cells (IC50 = 0.38 nM) and bone resorption from neonatal mouse calvariae in vitro. In vivo, PTH (1-34) (40 µg/kg per day) increases bone mass in an ovariectomized adult rat model of postmenopausal osteoporosis.3 It also increases proteoglycan content and inhibits articular cartilage degeneration in knee joints in a mouse model of injury-induced osteoarthritis when administered at a dose of 40 µg/kg per day immediately following injury.4 Formulations containing PTH (1-34) have been used in the treatment of osteoporosis in men and postmenopausal women who are at high risk for fracture.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Madore, G.R., Sherman, P.J., and Lane, J.M. Parathyroid Hormone. J. Am. Acad. Orthop. Surg. 12(2), 67-71 (2004).

    2. Frolik, C.A., Cain, R.L., Sato, M., et al. Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats. J. Bone Miner. Res. 14(2), 163-172 (1999).

    3. Stewart, A.F., Cain, R.L., Burr, D.B., et al. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J. Bone Miner. Res. 15(8), 1517-1525 (2000).

    4. Sampson, E.R., Hilton, M.J., Tian, Y., et al. Teriparatide, a chondro-regenerative therapy for injury-induced osteoarthritis. Sci. Transl. Med. 3(101), 101ra193 (2011).